business.financialpost.com
Valeant Pharmaceuticals International Inc price target slashed, stock downgraded at RBC
Valeant Pharmaceuticals International Inc.’s disclosure that it is the subject of an SEC probe was enough to convince Douglas Miehm at RBC Capital Markets to finally downgrade the stock